0000000000337566
AUTHOR
A Chirianni
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART
Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to s…
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA â¤50 cp/mL
Background: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. Objectives: We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus raltegravir (RAL) while having a viral load (VL) â¤50 copies/mL in the clinical setting. Study design: Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA â¤50 copies/mL. Different defin…
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART
The extent to which HIV-1 proviral DNA mutations cause clinically relevant antiretroviral resistance is still controversial. Paired plasma HIV-1 RNA and whole blood DNA were compared in patients failing HAART to investigate if the additional knowledge of archived mutations could improve the selection of potentially active drugs. Seventy-three HIV-1-infected patients with first/second HAART failure were studied before starting a new regimen based on RNA genotyping. Follow-up data after a 12-week therapy were available. DNA genotyping was retrospectively performed on stored whole blood samples and mutational profiles were compared to those from RNA. The mean number of IAS pol mutations was si…
HIGH VISCERAL ADIPOSITY INDEX (VAI) SCORE BEFORE AND AFTER TREATMENT IN YOUNGH HIV-POSITIVE PATIENTS
The new therapies in HIV-positive patients are extremely effective in terms of immunological response. In western countries the mortality rate was reduced by 100% from 1984 to the current 8.8%. HIV people are now patients with a chronic disease characterized by also metabolic disorders. Long term virus alterations and treatment sideeffects induced lipid disorders, in particular hypercholesterolemia and hypertriglyceridemia. To assess cardiovascular risk (CVR) in HIV patients. From April 2012 to January 2013 we evaluated 20 HIV-positive naive patients, no HBV-HCV coinfected (19 males, age range 21-42 years, mean 31.8 + 4.8, BMI 23.5 + 3.8). Before and after inhibitor proteases (IP) treatment…